Logo
job logo

Associate Director/Director/Sr. Director, Oligonucleotide Chemistry, Woburn

Vivatides Therapeutics Inc., Woburn, MA, United States


As an exciting start‑up, we offer an amazing opportunity to develop the next generation RNA therapeutics. We are seeking a well‑organized and self‑motivated senior scientist to join our company site in Woburn, MA. The successful candidate will be a key member of the drug discovery group and will lead efforts to advance siRNA/ASO therapeutics to treat intractable diseases. Strong knowledge of oligonucleotide drug design and experience in organic chemistry of oligonucleotide precursors, respective delivery vehicles and methods is a must. Experience in oligonucleotide post‑conjugation methods is a strong plus. Experience of work with oligo synthesizers is a plus but not required. Proven track record of leadership of successful projects in oligonucleotide drug discovery and strong publication record of scientific papers and patents.

Primary Responsibilities:
  • Chemistry platform design and refining.
  • CMC planning.
  • Direct chemistry informatics (internal databases, literature and patent search).
  • Drafting of patent applications.
  • Oversee team performance.
  • Manage FFS/FTE projects with CROs.
  • Follow and further refine company standards of data collection, presentation, and QC.
  • May need to establish new specialized chemistry units, screen/recruit candidate chemists.
Qualifications:
  • Ph.D. in Organic or Medicinal Chemistry.
  • Minimum of 5 years of experience in oligonucleotide drug discovery, with at least 2 years in a leadership role.
  • Deep understanding of oligonucleotide and precursor synthesis, modification, purification, and conjugation mechanisms.
  • Familiarity with analytical methods and quality standards in oligonucleotide drug development.
  • Strong project management skills and cross‑functional communication abilities.

Seniority level

Director

Employment type

Full‑time

Referrals increase your chances of interviewing at Vivatides Therapeutics Inc. by 2x

#J-18808-Ljbffr